MDX-1097 (also called IST-1097) is a monoclonal antibody therapy being assessed in clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells.
References
MDX-1097 Wikipedia(Text) CC BY-SA